fluorodeoxyglucose f18 has been researched along with su 11248 in 27 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (14.81) | 29.6817 |
| 2010's | 21 (77.78) | 24.3611 |
| 2020's | 2 (7.41) | 2.80 |
| Authors | Studies |
|---|---|
| Banzo, I; Barragan, J; Carril, JM; Jimenez-Bonilla, J; Martinez-Rodriguez, I; Portilla-Quattrociocchi, H; Quirce, R; Sainz-Esteban, A | 1 |
| Benhattar, J; Delaloye, AB; Elsig, V; Guillou, L; Leyvraz, S; Luthi, F; Michielin, O; Montemurro, M; Orcurto, MV; Prior, JO; Stupp, R | 1 |
| Baillet, G; Barré, E; Bousquet, G; Desgrandchamps, F; Hindié, E; Just, PA; Mathieu, O; Misset, JL; Moretti, JL; Vercellino, L | 1 |
| Antonescu, CR; Baum, CM; Bello, CL; Chen, MH; Cohen, DP; Corless, CL; Demetri, GD; Fletcher, CD; Fletcher, JA; George, S; Heinrich, MC; Huang, X; Maki, RG; Morgan, JA; Van den Abbeele, AD | 1 |
| Bauman, JE; Capell, PT; Carr, LL; Eaton, KD; Goulart, BH; Kell, EM; Mankoff, DA; Martins, RG | 1 |
| Brouwers, AH; de Jong, JR; de Vries, EG; den Dunnen, WF; Elsinga, PH; Gietema, JA; Hesselink, JW; Hollema, H; Hospers, GA; Lub-de Hooge, MN; Nagengast, WB; Oosting, SF; Price, PM; Warnders, FJ | 1 |
| Fjeld, JG; Fosså, SD; Hagen, G; Lilleby, W; Revheim, ME; Winge-Main, AK | 1 |
| Avril, N; Bomanji, J; Chowdhury, S; Dickson, J; Ell, P; Kayani, I; Lim, L; Nathan, P; Powles, T; Reynolds, A; Rockall, A; Sahdev, A; Shamash, J; Sharpe, K; Wilson, P | 1 |
| Hayashi, N; Ikeda, I; Inoue, T; Kishida, T; Kobayashi, K; Kubota, Y; Makiyama, K; Minamimoto, R; Miura, T; Murakami, T; Nakaigawa, N; Noguchi, S; Ohgo, Y; Sano, F; Tateishi, U; Ueno, D; Yao, M | 1 |
| Aide, N; Bardet, S; Crouzeix, G; Michels, JJ; Sevin, E; Vaur, D | 1 |
| Gallowitsch, HJ; Malle, P; Sorschag, M | 1 |
| Behrendt, FF; Bzyl, J; Mottaghy, FM; Palmowski, K; Palmowski, M; Rix, A; Verburg, FA; Winz, O | 1 |
| Chen, J; Cong, L; Cui, Y; Han, J; Luan, Y; Sha, D; Shen, R; Wang, C; Wang, W; Zhang, Z | 1 |
| Berney, D; Bex, A; Blank, C; Boleti, E; Chowdhury, S; Haanen, J; Jones, R; Kayani, I; Lim, L; Peters, J; Powles, T; Reynolds, AR; Sahdev, A; Shamash, J; Sharpe, K; Stewart, GD | 1 |
| Aboagye, EO; Ashek, A; Barnes, G; Cotroneo, E; Cupitt, J; Dabral, S; Dubois, O; El-Bahrawy, MA; Fang, W; Gibbs, JS; Gsell, W; He, JG; Howard, LS; Jones, H; Nguyen, QD; Pullamsetti, SS; Tomasi, G; Wang, L; Wilkins, MR; Zhao, L | 1 |
| Behrendt, FF; Gray, BD; Kiessling, F; Lederle, W; Mottaghy, FM; Pak, KY; Palmowski, K; Palmowski, M; Rix, A | 1 |
| Blomqvist, LK; Farnebo, J; Grybäck, P; Harmenberg, U; Laurell, A; Sandström, P; Ullén, A; Wersäll, P | 1 |
| Bernards, N; Beynel, A; Boisgard, R; Bouet, S; Buvat, I; Kuhnast, B; Tavitian, B; Thézé, B | 1 |
| Agarwal, N; Beardmore, B; Boucher, K; Butterfield, RI; Hoffman, JM; Horn, KP; Kadrmas, DJ; Morton, KA; Yap, JT | 1 |
| Amantea, MA; Friberg, LE; Karlsson, MO; Schindler, E | 1 |
| Bai, R; Li, J; Li, Y; Ma, Y; Shi, H; Wang, C; Xiao, J; Xu, W; Yang, C; Yu, H; Zhang, J | 1 |
| Alamanou, M; Arany, Z; Byrne, AT; Cary, M; Conroy, E; Cutler, P; Ducret, A; Evans, R; Force, T; Gallagher, WM; Gascon, S; Hector, S; Jarzabek, MA; Jauhiainen, M; Knuuti, J; Ky, B; Lecomte, R; Liljenbäck, H; Maratha, A; McAuliffe, FM; Miller, IS; Murray, DW; O'Farrell, AC; Oikonen, V; Pallaud, C; Roivainen, A; Rousseau, JA; Saraste, A; Shiels, L; Silvola, JM; Udupi, GM | 1 |
| Cho, A; Choi, YD; Hwang, SH; Kang, WJ; Rha, SY; Yun, M | 1 |
| Cook, G; Goh, V; Kelly-Morland, C; Mallett, S; Montana, G; Nathan, P; Rudman, S | 1 |
| Adler, SS; Basuli, F; Choyke, PL; Green, MV; Jagoda, EM; Kuo, F; Roy, J; Seidel, J; Williams, MR; Wong, K; Xu, B | 1 |
| Agrawal, A; Purandare, N; Puranik, A; Rangarajan, V; Shah, S; Suthar, RR | 1 |
| Autret, G; Balvay, D; Braik-Djellas, Y; Favier, J; Gimenez-Roqueplo, AP; Lussey-Lepoutre, C; Moog, S; Robidel, E; Salgues, B; Tavitian, B; Viel, T | 1 |
1 review(s) available for fluorodeoxyglucose f18 and su 11248
| Article | Year |
|---|---|
FDG PET and FDG PET/CT in patients with gastrointestinal stromal tumours.
Topics: Antineoplastic Agents; Benzamides; Blood Glucose; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Molecular Targeted Therapy; Multimodal Imaging; Neoplasm Recurrence, Local; Piperazines; Positron-Emission Tomography; Prognosis; Pyrimidines; Pyrroles; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
11 trial(s) available for fluorodeoxyglucose f18 and su 11248
| Article | Year |
|---|---|
Early prediction of response to sunitinib after imatinib failure by 18F-fluorodeoxyglucose positron emission tomography in patients with gastrointestinal stromal tumor.
Topics: Adult; Aged; Antineoplastic Agents; Benzamides; Disease Progression; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Mutation; Piperazines; Positron-Emission Tomography; Protein-Tyrosine Kinases; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Receptor, Platelet-Derived Growth Factor alpha; Salvage Therapy; Sunitinib | 2009 |
18F-FDG PET/CT imaging for an early assessment of response to sunitinib in metastatic renal carcinoma: preliminary study.
Topics: Aged; Aged, 80 and over; Antineoplastic Agents; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indoles; Kidney Neoplasms; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Radiopharmaceuticals; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2009 |
Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure.
Topics: Adult; Aged; Benzamides; Cell Proliferation; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Imatinib Mesylate; Indoles; Male; Middle Aged; Piperazines; Positron-Emission Tomography; Proto-Oncogene Proteins c-kit; Pyrimidines; Pyrroles; Sunitinib; Treatment Failure | 2009 |
Phase II study of daily sunitinib in FDG-PET-positive, iodine-refractory differentiated thyroid cancer and metastatic medullary carcinoma of the thyroid with functional imaging correlation.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma; Carcinoma, Medullary; Cell Differentiation; Drug Administration Schedule; Drug Resistance, Neoplasm; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine; Male; Middle Aged; Neoplasm Metastasis; Positron-Emission Tomography; Pyrroles; Sunitinib; Thyroid Neoplasms; Tomography, Emission-Computed; Treatment Failure | 2010 |
Sequential FDG-PET/CT as a biomarker of response to Sunitinib in metastatic clear cell renal cancer.
Topics: Adult; Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Kaplan-Meier Estimate; Kidney Neoplasms; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Pyrroles; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2011 |
A prospective evaluation of VEGF-targeted treatment cessation in metastatic clear cell renal cancer.
Topics: Adult; Aged; Aged, 80 and over; Angiogenesis Inhibitors; Carcinoma, Renal Cell; Disease-Free Survival; Drug Administration Schedule; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Nephrectomy; Positron-Emission Tomography; Prospective Studies; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sulfonamides; Sunitinib; Treatment Outcome; Vascular Endothelial Growth Factor A; Withholding Treatment | 2013 |
Heterogeneity in lung (18)FDG uptake in pulmonary arterial hypertension: potential of dynamic (18)FDG positron emission tomography with kinetic analysis as a bridging biomarker for pulmonary vascular remodeling targeted treatments.
Topics: Adult; Aged; Animals; Benzamides; Cell Division; Dichloroacetic Acid; Disease Models, Animal; Drug Monitoring; Familial Primary Pulmonary Hypertension; Female; Fibroblasts; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Gene Expression Profiling; Glycolysis; Humans; Hypertension, Pulmonary; Imatinib Mesylate; Indoles; Lung; Male; Middle Aged; Monocrotaline; Piperazines; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrimidines; Pyrroles; Radiopharmaceuticals; Rats; Rats, Sprague-Dawley; Sunitinib; Young Adult | 2013 |
FDG and FLT-PET for Early measurement of response to 37.5 mg daily sunitinib therapy in metastatic renal cell carcinoma.
Topics: Aged; Aged, 80 and over; Angiogenesis Inhibitors; Antineoplastic Agents; Carcinoma, Renal Cell; Dideoxynucleosides; Female; Fluorine Radioisotopes; Fluorodeoxyglucose F18; Humans; Image Processing, Computer-Assisted; Indoles; Kidney Neoplasms; Male; Middle Aged; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Treatment Outcome | 2015 |
PK-PD modeling of individual lesion FDG-PET response to predict overall survival in patients with sunitinib-treated gastrointestinal stromal tumor.
Topics: Adult; Fluorodeoxyglucose F18; Gastrointestinal Neoplasms; Gastrointestinal Stromal Tumors; Humans; Indoles; Models, Biological; Models, Statistical; Nonlinear Dynamics; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Sunitinib; Survival Analysis; Survival Rate; Treatment Outcome; Tumor Burden | 2016 |
Volume-based predictive biomarkers of sequential FDG-PET/CT for sunitinib in cancer of unknown primary: identification of the best benefited patients.
Topics: Adult; Antineoplastic Agents; Biomarkers; China; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Neoplasms, Unknown Primary; Outcome Assessment, Health Care; Patient Selection; Positron Emission Tomography Computed Tomography; Prevalence; Prognosis; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; Risk Factors; Sensitivity and Specificity; Sunitinib; Survival Rate; Treatment Outcome; Tumor Burden | 2017 |
Evaluation of treatment response and resistance in metastatic renal cell cancer (mRCC) using integrated
Topics: Adult; Aged; Axitinib; Bevacizumab; Carcinoma, Renal Cell; Cell Proliferation; Contrast Media; Female; Fluorodeoxyglucose F18; Humans; Imidazoles; Indazoles; Indoles; London; Male; Middle Aged; Multimodal Imaging; Neoplasm Metastasis; Neoplasms, Second Primary; Positron-Emission Tomography; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2017 |
15 other study(ies) available for fluorodeoxyglucose f18 and su 11248
| Article | Year |
|---|---|
F-18 FDG PET/CT assessment of gastrointestinal stromal tumor response to sunitinib malate therapy.
Topics: Antineoplastic Agents; Female; Fluorodeoxyglucose F18; Gastrointestinal Stromal Tumors; Humans; Indoles; Liver Neoplasms; Middle Aged; Pyrroles; Radiography; Radionuclide Imaging; Radiopharmaceuticals; Sunitinib | 2008 |
VEGF-PET imaging is a noninvasive biomarker showing differential changes in the tumor during sunitinib treatment.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Biomarkers, Tumor; Fluorodeoxyglucose F18; Humans; Indoles; Male; Mice; Mice, Nude; Positron-Emission Tomography; Pyrroles; Sunitinib; Transplantation, Heterologous; Vascular Endothelial Growth Factor A | 2011 |
Combined positron emission tomography/computed tomography in sunitinib therapy assessment of patients with metastatic renal cell carcinoma.
Topics: Aged; Antineoplastic Agents; Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Indoles; Kidney Neoplasms; Middle Aged; Positron-Emission Tomography; Protein Kinase Inhibitors; Pyrroles; Sunitinib; Tomography, X-Ray Computed | 2011 |
Early assessment by FDG-PET/CT of patients with advanced renal cell carcinoma treated with tyrosine kinase inhibitors is predictive of disease course.
Topics: Adult; Aged; Aged, 80 and over; Benzenesulfonates; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Humans; Indoles; Male; Middle Aged; Multimodal Imaging; Neoplasm Staging; Niacinamide; Phenylurea Compounds; Positron-Emission Tomography; Prognosis; Protein Kinase Inhibitors; Pyridines; Pyrroles; Sorafenib; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2012 |
Unusual short-term complete response to two regimens of cytotoxic chemotherapy in a patient with poorly differentiated thyroid carcinoma.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents, Phytogenic; Antineoplastic Combined Chemotherapy Protocols; Benzenesulfonates; Cisplatin; Combined Modality Therapy; Doxorubicin; Fatal Outcome; Female; Fluorodeoxyglucose F18; Humans; Indoles; Iodine Radioisotopes; Lung Neoplasms; Middle Aged; Niacinamide; Paclitaxel; Phenylurea Compounds; Piperidines; Pyridines; Pyrroles; Quinazolines; Radiopharmaceuticals; Sorafenib; Sunitinib; Thyroid Neoplasms; Thyroidectomy; Tomography, X-Ray Computed | 2012 |
Accuracy of a clinical PET/CT vs. a preclinical μPET system for monitoring treatment effects in tumour xenografts.
Topics: Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Drug Monitoring; Equipment Design; Equipment Failure Analysis; Female; Fluorodeoxyglucose F18; Indoles; Mice; Mice, Nude; Multimodal Imaging; Neoplasms, Experimental; Positron-Emission Tomography; Pyrroles; Radiopharmaceuticals; Reproducibility of Results; Sensitivity and Specificity; Sunitinib; Tomography, X-Ray Computed; Treatment Outcome | 2013 |
Therapeutic effect of sunitinib malate and its influence on blood glucose concentrations in a patient with metastatic insulinoma.
Topics: Aged; Antineoplastic Agents; Blood Glucose; Fluorodeoxyglucose F18; Humans; Indoles; Insulinoma; Liver Neoplasms; Male; Positron-Emission Tomography; Pyrroles; Sunitinib; Tomography, Emission-Computed | 2013 |
A low molecular weight zinc2+-dipicolylamine-based probe detects apoptosis during tumour treatment better than an annexin V-based probe.
Topics: Amines; Angiogenesis Inhibitors; Animals; Annexin A5; Apoptosis; Carcinoma, Squamous Cell; Female; Fluorodeoxyglucose F18; Humans; Immunohistochemistry; Indoles; Mice; Mice, Nude; Molecular Probes; Molecular Weight; Neoplasms, Experimental; Organometallic Compounds; Picolinic Acids; Pyrroles; Skin Neoplasms; Sunitinib; Tumor Cells, Cultured; Zinc | 2014 |
Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma.
Topics: Aged; Carcinoma, Renal Cell; Cone-Beam Computed Tomography; Disease-Free Survival; Female; Fluorodeoxyglucose F18; Humans; Indazoles; Indoles; Kaplan-Meier Estimate; Male; Middle Aged; Molecular Targeted Therapy; Neoplasm Metastasis; Positron-Emission Tomography; Prognosis; Protein-Tyrosine Kinases; Pyrimidines; Pyrroles; Sulfonamides; Sunitinib; Treatment Outcome | 2014 |
Monitoring therapeutic efficacy of sunitinib using [(18)F]FDG and [(18)F]FMISO PET in an immunocompetent model of luminal B (HER2-positive)-type mammary carcinoma.
Topics: Animals; Antineoplastic Agents; Apoptosis; Breast Neoplasms; Cell Proliferation; Disease Models, Animal; Female; Fluorodeoxyglucose F18; Gene Expression Regulation, Neoplastic; Glucose Transporter Type 1; Humans; Hypoxia-Inducible Factor 1, alpha Subunit; Indoles; Mice; Misonidazole; Positron-Emission Tomography; Pyrroles; Sunitinib | 2015 |
A Novel Positron Emission Tomography (PET) Approach to Monitor Cardiac Metabolic Pathway Remodeling in Response to Sunitinib Malate.
Topics: Animals; Fluorodeoxyglucose F18; Heart; Humans; Indoles; Male; Metabolic Networks and Pathways; Myocardium; Positron-Emission Tomography; Proteomics; Pyrroles; Rats; Rats, Sprague-Dawley; Sunitinib; Ventricular Function, Left | 2017 |
Prognostic Value of Pretreatment Metabolic Tumor Volume and Total Lesion Glycolysis Using 18F-FDG PET/CT in Patients With Metastatic Renal Cell Carcinoma Treated With Anti-Vascular Endothelial Growth Factor-Targeted Agents.
Topics: Adult; Aged; Aged, 80 and over; Carcinoma, Renal Cell; Female; Fluorodeoxyglucose F18; Glycolysis; Humans; Indazoles; Indoles; Kidney Neoplasms; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Positron Emission Tomography Computed Tomography; Pyrimidines; Pyrroles; Radiopharmaceuticals; Sorafenib; Sulfonamides; Sunitinib | 2017 |
The Distribution Volume of
Topics: Albumins; Angiogenesis Inhibitors; Animals; Antineoplastic Agents; Cell Line, Tumor; Female; Fluorodeoxyglucose F18; Humans; Mice; Mice, Nude; Neoplasms; Neovascularization, Pathologic; Positron-Emission Tomography; Radiopharmaceuticals; Sunitinib; Tissue Distribution; Treatment Outcome; Xenograft Model Antitumor Assays | 2019 |
Sunitinib-Induced Myositis Detected on 18F-FDG PET/CT.
Topics: Carcinoma, Renal Cell; Fluorodeoxyglucose F18; Humans; Kidney Neoplasms; Myositis; Positron Emission Tomography Computed Tomography; Positron-Emission Tomography; Sunitinib | 2022 |
Preclinical evaluation of targeted therapies in Sdhb-mutated tumors.
Topics: Adrenal Gland Neoplasms; Animals; Antineoplastic Agents; Fluorodeoxyglucose F18; Humans; Mice; Mutation; Paraganglioma; Pheochromocytoma; Succinate Dehydrogenase; Succinates; Sunitinib | 2022 |